Can a double immunotherapy beat standard care for a tough stomach cancer?

NCT ID NCT07127822

Recruiting now Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This phase II trial is comparing a new combination of two immunotherapies (iparomlimab and tuvonralimab) against standard chemotherapy plus a PD-1/PD-L1 inhibitor as a first-line treatment for people with recurrent or metastatic gastric cancer that is MSI-H or dMMR. The study aims to see if the experimental combo is at least as effective as the standard approach in shrinking tumors and delaying progression. About 106 adults with this specific cancer type will be enrolled to evaluate response rates and survival outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and tuvonralimab (a combination of two experimental immunotherapies)
What this could lead to: If successful, this could offer a new first-line treatment option for people with a specific type of advanced gastric cancer, potentially improving tumor shrinkage and survival compared to standard therapy.
What could go wrong: This is a phase II trial, so results are preliminary and may not hold up in larger studies. Immunotherapies can cause immune-related side effects, and the experimental combo might not prove as effective as standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA MSI-H CANCER

Contacts and locations

Locations

Department of GI Oncology, Peking University Cancer Hospital
RECRUITING

Beijing, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China
Jiangsu Provincial People's Hospital
RECRUITING

Nanjing, Jiangsu, China
Shanxi Cancer Hospital
RECRUITING

Taiyuan, Shanxi, China
The Affiliated Hospital of Qingdao University
RECRUITING

Qingdao, Shandong, China
The First Affiliated Hospital of Xi'an Jiao Tong University）
RECRUITING

Xi'an, Shaanxi, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
The Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, Tianjin Municipality, China
West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.